MoonLake Immunotherapeutics: financial statements

MLTXNASDAQHealthcare · Pharmaceutical Preparations

Price

$11.07

November 20, 2026Market cap $942M

What Ploutos Investor adds for MoonLake Immunotherapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 5 fiscal years, from 2021
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2023–2025 fiscal years

Click a line to see it on the chart.

Operating income

Line202320242025Average a year
Operating income -$54M-$143M-$245M
Net income -$36M-$119M-$227M
Earnings per share -$0.73-$1.89-$3.53
Earnings per share, basic -$0.73-$1.89-$3.53

Financial statements

MLTX's revenue, profits and cash flows from 2021 to 2022, 2 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$1.6M Leases100% Pensions funded-0.3% Effective tax rate

Leases

Dec 31, 2025

Operating leases

$1.6M

Finance leases

–

Average discount rate
4.6%
Lease cost for the year
$1.5M

The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing

Operating lease payments by year

Lease liability by year

Leases

MLTX's leases from 2022 to 2022, 1 more fiscal year

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 4 fiscal years.

Pension plans

Dec 31, 2025

Defined-benefit pensions

100%funded

Surplus $9.0K.

The obligation is the present value of the pensions employees have already earned, at December 31, 2025. A deficit is the company's to fill with contributions. The filing

ObligationPlan assets

Pensions funded, by year

Pensions funded, by year

How far MLTX's pension plans were funded, from 2022 to 2022, 1 more fiscal year

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 4 fiscal years.

From the statutory to the effective tax rate, 2025

Dec 31, 2025

Statutory rate

8.5%

Effective rate

-0.3%

-8.8 pts

The company paid -0.3% in tax on its profit, 8.8 points below the statutory rate it starts from (8.5%). Below, the reasons it gives.

Statutory rate

8.5%

Change in valuation allowance

-8.4 pts

Smaller lines (3)

-0.4 pts

Effective rate

-0.3%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

Effective tax rate by year

In a year of a loss or of very small profits the rate comes out negative or very large and says little. Those years are in grey.

Effective tax rate by year

The tax rate MLTX paid on its profit, from 2022 to 2022, 1 more fiscal year

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 4 fiscal years.

The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.

The full analysis

What do MoonLake Immunotherapeutics's filings show?

These are MoonLake Immunotherapeutics's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about MLTX's financials

Didn't find what you were looking for?

Ask us
How much debt does MLTX have?

On December 31, 2025 MoonLake Immunotherapeutics had total assets of $424M, debt of $74M and shareholders' equity of $304M.

How much free cash flow does MLTX have?

In fiscal 2025 MoonLake Immunotherapeutics had cash from operations of -$196M and spent $35.0K on capital expenditure, leaving -$196M of free cash flow.

Where are the figures from?

From MoonLake Immunotherapeutics's annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.